Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 0.29
MNKD's Cash to Debt is ranked lower than
91% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 42.60 vs. MNKD: 0.29 )
Ranked among companies with meaningful Cash to Debt only.
MNKD' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 0.33 Max: No Debt
Current: 0.29
F-Score: 1
Z-Score: -38.73
M-Score: -12.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROA (%) -183.75
MNKD's ROA (%) is ranked lower than
94% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. MNKD: -183.75 )
Ranked among companies with meaningful ROA (%) only.
MNKD' s ROA (%) Range Over the Past 10 Years
Min: -183.75  Med: -66.24 Max: -54.14
Current: -183.75
-183.75
-54.14
ROC (Joel Greenblatt) (%) -325.72
MNKD's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -387.57 vs. MNKD: -325.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MNKD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -325.72  Med: -96.5 Max: -70.3
Current: -325.72
-325.72
-70.3
EBITDA Growth (3Y)(%) -25.70
MNKD's EBITDA Growth (3Y)(%) is ranked lower than
78% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. MNKD: -25.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MNKD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -43  Med: -24.8 Max: 10.9
Current: -25.7
-43
10.9
EPS Growth (3Y)(%) -27.20
MNKD's EPS Growth (3Y)(%) is ranked lower than
78% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. MNKD: -27.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MNKD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -42.9  Med: -23 Max: 7.6
Current: -27.2
-42.9
7.6
» MNKD's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

MNKD Guru Trades in Q3 2015

Paul Tudor Jones 43,922 sh (New)
Murray Stahl 217,952 sh (+39.98%)
» More
Q4 2015

MNKD Guru Trades in Q4 2015

Paul Tudor Jones 219,364 sh (+399.44%)
Murray Stahl 380,440 sh (+74.55%)
» More
Q1 2016

MNKD Guru Trades in Q1 2016

Murray Stahl Sold Out
Paul Tudor Jones 103,372 sh (-52.88%)
» More
Q2 2016

MNKD Guru Trades in Q2 2016

Paul Tudor Jones 103,325 sh (-0.05%)
» More
» Details

Insider Trades

Latest Guru Trades with MNKD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:VSAR, NAS:SRNE, NAS:TRVN, NAS:ARNA, NAS:NDRM, NAS:RVNC, NAS:CLDX, NAS:CGEN, NAS:TGTX, NAS:ADXS, NAS:CTMX, OTCPK:TYMI, NAS:SVA, NAS:TLGT, NAS:VYGR, NAS:NERV, NAS:RGNX, NAS:ARWR, NAS:NSTG, NAS:OMER » details
Traded in other countries:NNF1.Germany,
MannKind Corp is a development stage company engaged in the discovery, development, and commercialization of therapeutic products for diseases such as diabetes.

MannKind Corp a development stage biopharmaceutical company, was incorporated in the state of Delaware on February 14, 1991. The Company is engaged in the discovery, development and commercialization of therapeutic products for diseases such as diabetes. Its product candidate, AFREZZA inhalation powder, is an ultra rapid-acting insulin therapy that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Its other product MKC253, MKC253 is a Technosphere formulation of GLP-1. Results from a phase 1 trial supported the hypothesis that inhalation of MKC253 may be able to simulate the incretin effect that is lost in patients with type 2 diabetes. Products manufactured in the United States and marketed outside the United States are subject to certain FDA regulations, as well as regulation by the country in which the products are to be sold.

Ratios

vs
industry
vs
history
Current Ratio 0.31
MNKD's Current Ratio is ranked lower than
96% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. MNKD: 0.31 )
Ranked among companies with meaningful Current Ratio only.
MNKD' s Current Ratio Range Over the Past 10 Years
Min: 0.12  Med: 1.41 Max: 12.24
Current: 0.31
0.12
12.24
Quick Ratio 0.30
MNKD's Quick Ratio is ranked lower than
94% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. MNKD: 0.30 )
Ranked among companies with meaningful Quick Ratio only.
MNKD' s Quick Ratio Range Over the Past 10 Years
Min: 0.12  Med: 1.41 Max: 12.24
Current: 0.3
0.12
12.24

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -45.60
MNKD's 3-Year Average Share Buyback Ratio is ranked lower than
84% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.50 vs. MNKD: -45.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNKD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -58.3  Med: -42.9 Max: -8
Current: -45.6
-58.3
-8

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -66.27
MNKD's Earnings Yield (Greenblatt) (%) is ranked lower than
88% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.90 vs. MNKD: -66.27 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MNKD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -70.11  Med: 157.5 Max: 7504.7
Current: -66.27
-70.11
7504.7

More Statistics

EPS (TTM) $ -0.89
Beta2.40
Short Percentage of Float31.99%
52-Week Range $0.64 - 4.07
Shares Outstanding (Mil)478.05

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $)
EPS ($) -0.17 -0.15 -0.16
EPS w/o NRI ($) -0.17 -0.15 -0.16
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for MNKD

Headlines

Articles On GuruFocus.com
Why MannKind Could Be a Value Trap Jan 04 2016 
MannKind Corporation Disappoints with Afrezza Sales; Analysts Lower Expectations May 11 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 
Analysts Weigh in on MannKind Following Q4 Results Feb 27 2015 
What to Watch for: November 3-7 Nov 04 2014 
Roche to Acquire InterMune and Deliver Hope to Patients Worldwide Aug 25 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza Aug 15 2014 
There is a Tide in the Affairs of MannKind: When Taken At the Flood, Will Lead to Fortune Aug 14 2014 

More From Other Websites
MannKind Is 'Making Progress' On Its Alternative To Mylan's EpiPen, Report Says Aug 30 2016
Securities Class Action Against MannKind Dismissed Aug 25 2016
Securities Class Action Against MannKind Dismissed Aug 25 2016
Short Sellers Increase Bets in Major Biotechs Aug 25 2016
The 6 Most Shorted Nasdaq Stocks: Frontier in the Spotlight Aug 25 2016
MANNKIND CORP Financials Aug 18 2016
MANNKIND CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 10 2016
Short Sellers Run for Cover From Major Biotechs Aug 10 2016
The 6 Most Shorted Nasdaq Stocks: Intel Slips Down the List Aug 10 2016
MANNKIND CORP Files SEC form 10-Q, Quarterly Report Aug 09 2016
MannKind reports 2Q loss Aug 09 2016
MannKind reports 2Q loss Aug 09 2016
Edited Transcript of MNKD earnings conference call or presentation 8-Aug-16 9:00pm GMT Aug 08 2016
MannKind Corporation Reports 2016 Second Quarter Financial Results Aug 08 2016
MannKind Corporation Reports 2016 Second Quarter Financial Results Aug 08 2016
Q2 2016 MannKind Corp Earnings Release - After Market Close Aug 08 2016
What to Expect from MannKind's (MNKD) Q2 Earnings Report Aug 05 2016
MannKind Corporation to Hold 2016 Second Quarter Financial Results Conference Call on August 8, 2016 Aug 01 2016
MannKind Corporation to Hold 2016 Second Quarter Financial Results Conference Call on August 8, 2016 Aug 01 2016
Mannkind Assumes Responsibility for Distribution of Afrezza® and Launches Patient Reimbursement and... Aug 01 2016
Mannkind Assumes Responsibility for Distribution of Afrezza® and Launches Patient Reimbursement and... Aug 01 2016
Major Biotechs See Increased Short Interest Bets Jul 27 2016
The 6 Most Shorted Nasdaq Stocks: Intel and AMD Buck the Trend Jul 27 2016
The 6 Most Shorted Nasdaq Stocks: Bye-Bye Apple Jul 13 2016
MannKind Corporation to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference Jul 08 2016
MannKind Announces Late-Breaking Data Reinforcing Faster Onset and Shorter Duration of Action... Jun 12 2016
MannKind Announces Collaboration with JDRF Jun 10 2016
MannKind Announces Pricing of Registered Direct Public Offering of Common Stock and Warrants May 09 2016
MannKind reports 1Q loss May 09 2016
MannKind Corporation Reports 2016 First Quarter Financial Results May 09 2016
MannKind Corporation to Present at the Bank of America Merrill Lynch 2016 Health Care Conference May 05 2016
MannKind Corporation to Hold 2016 First Quarter Financial Results Conference Call on May 9, 2016 May 02 2016
Analyst Call Rescheduled to April 26, 2016 Apr 19 2016
MannKind Expands Commercial Capabilities With Two New Hires Apr 19 2016
MannKind Regains Afrezza® Marketing Rights Apr 05 2016
MannKind reports 4Q loss Mar 14 2016
MannKind Corporation to Hold Investor Conference Call on February 3, 2016 Jan 27 2016
MannKind Enters Into Collaboration and License Agreement Jan 21 2016
MannKind Provides Update on Senior Management Jan 11 2016
MannKind Corporation Announces Termination of License and Collaboration Agreement With Sanofi Jan 05 2016
MannKind Corporation to Present at the J.P. Morgan 2016 Healthcare Conference Dec 29 2015
MannKind Announces Appointment of Duane DeSisto as Chief Executive Officer Dec 23 2015
MannKind reports 3Q loss Nov 09 2015
MannKind reports 2Q loss Aug 10 2015
MannKind slumps after Sanofi details Afrezza sales Jul 30 2015
MannKind reports 4Q loss Feb 24 2015
MannKind reports 3Q loss Nov 03 2014
MannKind, Sanofi enter Afrezza deal worth $925M Aug 11 2014
Sanofi bets on inhaled insulin with MannKind deal Aug 11 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)